BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37757566)

  • 1. Imaging phenotypes predict overall survival in glioma more accurate than basic demographic and cell mutation profiles.
    Rathore S; Iftikhar MA; Chaddad A; Singh A; Gillani Z; Abdulkadir A
    Comput Methods Programs Biomed; 2023 Dec; 242():107812. PubMed ID: 37757566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural- and DTI- MRI enable automated prediction of IDH Mutation Status in CNS WHO Grade 2-4 glioma patients: a deep Radiomics Approach.
    Yuan J; Siakallis L; Li HB; Brandner S; Zhang J; Li C; Mancini L; Bisdas S
    BMC Med Imaging; 2024 May; 24(1):104. PubMed ID: 38702613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
    Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
    Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Machine learning and radiomic phenotyping of lower grade gliomas: improving survival prediction.
    Choi YS; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Jain R; Lee SK
    Eur Radiol; 2020 Jul; 30(7):3834-3842. PubMed ID: 32162004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas.
    Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY
    J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Automated machine learning to predict the co-occurrence of isocitrate dehydrogenase mutations and O
    Zhang S; Sun H; Su X; Yang X; Wang W; Wan X; Tan Q; Chen N; Yue Q; Gong Q
    J Magn Reson Imaging; 2021 Jul; 54(1):197-205. PubMed ID: 33393131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI Radiomic Features to Predict IDH1 Mutation Status in Gliomas: A Machine Learning Approach using Gradient Tree Boosting.
    Sakai Y; Yang C; Kihira S; Tsankova N; Khan F; Hormigo A; Lai A; Cloughesy T; Nael K
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33121211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Isocitrate Dehydrogenase (IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features.
    Peng H; Huo J; Li B; Cui Y; Zhang H; Zhang L; Ma L
    J Magn Reson Imaging; 2021 May; 53(5):1399-1407. PubMed ID: 33179832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining MRI and Histologic Imaging Features for Predicting Overall Survival in Patients with Glioma.
    Rathore S; Chaddad A; Iftikhar MA; Bilello M; Abdulkadir A
    Radiol Imaging Cancer; 2021 Jul; 3(4):e200108. PubMed ID: 34296969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging criteria for prediction of isocitrate dehydrogenase (IDH) mutation status in patients with grade II-III astrocytoma and oligodendroglioma.
    Çelik S; Öven BB; Demir MK; Yılmaz EÇ; Kanan D; Özdamarlar U; Emirzeoglu L; Yapıcıer Ö; Kılıç T
    Clin Neurol Neurosurg; 2021 Aug; 207():106745. PubMed ID: 34146841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel fully automated MRI-based deep-learning method for classification of IDH mutation status in brain gliomas.
    Bangalore Yogananda CG; Shah BR; Vejdani-Jahromi M; Nalawade SS; Murugesan GK; Yu FF; Pinho MC; Wagner BC; Mickey B; Patel TR; Fei B; Madhuranthakam AJ; Maldjian JA
    Neuro Oncol; 2020 Mar; 22(3):402-411. PubMed ID: 31637430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
    Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
    Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma.
    Joo B; Han K; Ahn SS; Choi YS; Chang JH; Kang SG; Kim SH; Zhou J; Lee SK
    Eur Radiol; 2019 Dec; 29(12):6643-6652. PubMed ID: 31175415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups.
    Juratli TA; Tummala SS; Riedl A; Daubner D; Hennig S; Penson T; Zolal A; Thiede C; Schackert G; Krex D; Miller JJ; Cahill DP
    J Neurooncol; 2019 Jan; 141(2):327-335. PubMed ID: 30536195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI.
    Fujii Y; Muragaki Y; Maruyama T; Nitta M; Saito T; Ikuta S; Iseki H; Hongo K; Kawamata T
    J Neurosurg; 2018 Jul; 129(1):1-9. PubMed ID: 28885120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning.
    Suchorska B; Schüller U; Biczok A; Lenski M; Albert NL; Giese A; Kreth FW; Ertl-Wagner B; Tonn JC; Ingrisch M
    Eur J Cancer; 2019 Jan; 107():15-27. PubMed ID: 30529899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI.
    Zhang X; Tian Q; Wang L; Liu Y; Li B; Liang Z; Gao P; Zheng K; Zhao B; Lu H
    J Magn Reson Imaging; 2018 Oct; 48(4):916-926. PubMed ID: 29394005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generative AI in glioma: Ensuring diversity in training image phenotypes to improve diagnostic performance for IDH mutation prediction.
    Moon HH; Jeong J; Park JE; Kim N; Choi C; Kim YH; Song SW; Hong CK; Kim JH; Kim HS
    Neuro Oncol; 2024 Jun; 26(6):1124-1135. PubMed ID: 38253989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.